2019 American Transplant Congress » Poster Session A: Kidney Immunosuppression: Novel Regimens and Drug Minimization

Date: Saturday, June 1, 2019

Time: 5:30pm-7:30pm

Location: Hall C & D

Session Type: Poster Session

Meeting: 2019 American Transplant Congress

5:30pm-7:30pm: A Naturalistic Study of De Novo Extended-Release Tacrolimus Tablets vs. Tacrolimus Immediate-Release Capsules in Kidney Transplant Recipients

T. A. Horwedel¹, C. E. Carthon¹, S. E. January¹, A. Gharabagi¹, R. Delos Santos², J. C. Hagopian¹

5:30pm-7:30pm: A Retrospective Observational Analysis of Tacrolimus Metabolism Rate: No Evidence for Impact on Renal Function

A. J. Hughes, J. E. Kimpton, I. MacPhee

5:30pm-7:30pm: Abatacept as Rescue Immunosuppression after Calcineurin Inhibitor Treatment Failure in Renal Transplantation

I. R. Badell, P. Vasanth, A. B. Farris, J. M. Robertson, G. M. Karadkhele, C. P. Larsen

5:30pm-7:30pm: Adverse Effect Differences between Tacrolimus-IR and LCP-Tacrolimus

J. Hagopian¹, C. Carthon¹, S. January¹, A. Gharabagi², R. Delos Santos³, T. Horwedel⁴

5:30pm-7:30pm: Assessment of Proteinuria Reported as Adverse Events in De Novo Renal Transplant Recipients Receiving an Everolimus-Based Regimen: 24-Month Results from TRANSFORM

C. Legendre¹, S. Berger¹, F. Oppenheimer¹, A. Wiseman¹, S. Steinberg¹, O. Viklicky¹, G. Russ¹, R. Danguilan¹, N. Basic-Jukic¹, E. Mor¹, P. Narvekar², M. P. Hernandez Gutierrez², P. Bernhardt², C. Sommerer¹

5:30pm-7:30pm: Belatacept Conversion for Calcineurin Inhibitor-Associated Thrombotic Microangiopathy in Kidney Transplant Recipients

S. A. Muhsin, K. Safa, H. M. Gilligan, E. C. Heher, W. W. Williams, D. M. Wojciechowski

5:30pm-7:30pm: Belatacept Use in High Kidney Donor Profile Index Kidney Transplant Recipients

D. Britt¹, A. Gharabagi¹, K. Botkin¹, T. Horwedel², C. Carthon¹, J. Hagopian¹

5:30pm-7:30pm: CYP3A5 Genotype Had No Influence on Renal Function after Renal Transplantation

J. E. Kimpton, A. J. Hughes, I. MacPhee

5:30pm-7:30pm: Calcineurin Inhibitor Holiday for Management of Post Transplant Acute Kidney Injury

S. Sriperumbuduri, D. Lazarus, T. Fairhead, S. Hoar, J. Karpinski, G. Knoll

5:30pm-7:30pm: Chloroquine’s Effect on T cell Proliferation

R. Muschalek¹, P. Jindra², R. Kerman², M. Kueht², W. Etheridge², M. Cusick²

5:30pm-7:30pm: Clinical Impact of Race and Timing of Acute Rejection on Recipients of Kidney Transplant on Early Steroid Withdrawal Protocol

O. Adebiyi, S. Yaqub, W. Goggins, D. Mishler, T. Taber, A. Sharfuddin

5:30pm-7:30pm: Clinical Implications of Belatacept Conversion in a High-Risk, Urban Renal Transplant Population

B. Valdepenas, J. Benken, E. Benedetti, Z. Hajjiri, A. Lichvar

5:30pm-7:30pm: Combination of Extended-Release Tacrolimus Plus Everolimus Once Daily in De Novo Kidney Transplant Recipients: ER-Tac vs LCPT

G. Spagnoletti, M. P. Salerno, F. De Gennaro, J. Romagnoli, F. Citterio

5:30pm-7:30pm: Comparison of Initial Sirolimus (SRL) and Everolimus (EVR) Exposure Patterns in Kidney Transplant Recipients

C. Rosso Felipe, L. Viana, M. Pontello Cristelli, M. Nakamura, L. Ramagnoli, S. Braga, V. Lima, A. Carnevalle, D. Casarini, J. Medina Pestana, H. Tedesco Silva Junior

5:30pm-7:30pm: Conversion from Tacrolimus Immediate Release to Tacrolimus Extended Release (Envarsus XR®): A Real World Cohort Highlighting Dosing Variability among Patients

K. D. Belfield¹, D. Malhotra², M. Waleed³, E. A. Cohen¹

5:30pm-7:30pm: Conversion to Belatacept in Kidney Transplant Recipients with Systemic Lupus Erythematosus

I. Carrión Barberà, M. C. Fajardo, D. Tsapepas, J. Gartshteyn, A. Askanase, H. E. Fernandez

5:30pm-7:30pm: De Novo Belatacept to Delay Tacrolimus Initiation in Renal Transplants with Delayed Graft Function

A. Dao, A. Reyad, L. Kautzman, M. Madhrira, I. Memon, O. Elmhishi, B. Sankarapandian, J. Johnson, S. Patel, S. Allam

5:30pm-7:30pm: Delayed Achievement of Therapeutic Tacrolimus Levels with De Novo Extended-Release Tacrolimus Tablets and the Incidence of Rejection in Kidney Transplant Patients

C. E. Carthon¹, J. C. Hagopian¹, S. E. January¹, A. Gharabagi¹, R. Delos Santos², T. A. Horwedel³

5:30pm-7:30pm: Difference in DSA Formation between Tacrolimus-XR and Tacrolimus-IR

J. Hagopian¹, C. Carthon¹, S. January¹, A. Gharabagi², R. Delos Santos³, T. Horwedel⁴

5:30pm-7:30pm: Dosing Requirements Of Astagraf Xl In African American Kidney Transplant Recipients Converted From Twice-daily Tacrolimus (aaaktrs)

J. N. Fleming, M. A. Posadas-Salas, D. J. Taber

5:30pm-7:30pm: Dosing and Exposure over 2 Years with LCP-Tacrolimus (LCPT) vs. Immediate-Release Tacrolimus (IR-Tac) in De Novo Kidney Transplantation

K. Budde¹, S. Bunnapradist², S. Patel³, D. Stevens³, U. Meier-Kriesche³, B. Suwelack⁴

5:30pm-7:30pm: Early Conversion to Belatacept in High Risk Renal Transplant Recipients

A. Santeusanio, A. Bhansali, R. Shapiro, V. Delaney, S. Florman, G. De Boccardo

5:30pm-7:30pm: Early Rejection Outcomes with IL-2 vs. ATG Induction among Kidney Transplant Recipients Induction Differences with Early Steroid Withdrawal

C. Burelli, A. Szczepanik, K. Yadav, E. Sanchez, M. Debroy, V. Humphreville, J. Rabets, A. Padiyar, N. Sarabu, A. Jittirat, A. Palanisamy, K. Chavin

5:30pm-7:30pm: Early Tacrolimus Trough Attainment in De Novo Kidney Transplant Recipients Treated with LCP-Tacrolimus (LCPT) vs. Immediate-Release Tacrolimus (IR-Tac)

K. Budde¹, S. Bunnapradist², S. J. Patel³, D. R. Stevens³, U. Meier-Kriesche³, B. Suwelack⁴

5:30pm-7:30pm: Eculizumab in Kidney Transplant Recipients with Atypical Hemolytic Uremic Syndrome – Single Center Experience

A. Bhalla, S. Alasfar, N. Alachkar

5:30pm-7:30pm: Effect of Everolimus on IgM and IgG Memory B Cell Growth and Survival In Vitro and Applications for Effective Administration in Clinical Practice

Y. Matsuda

5:30pm-7:30pm: Efficacy of Belatacept Conversion Protocols

M. Yazdi, J. Kahwaji, S. Meguerditchian, R. Lee

5:30pm-7:30pm: Evaluation of Envarsus XR in African American Kidney Transplant Recipients

L. R. Lineberger¹, E. Hollinger², N. Kenyon¹, M. Brokohf¹, N. Alvey¹

5:30pm-7:30pm: Everolimus/Low Tacrolimus Exposure versus Sodium Mycophenolate/Standard Tacrolimus for the Elderly Kidney Transplant Recipient. A 4-y Follow-Up of the nEverOld Trial

E. David-Neto, F. Agena, F. J. Paula, N. Z. Galante, D. S. David, F. Ramos, A. K. Triboni, P. Romano, P. A. Ebner, V. Coelho, M. Altona, R. Falci, A. Piovesan, W. C. Nahas

5:30pm-7:30pm: Impact of HLA-DR Matching on HLA-DQ Matching Status and the Development of Anti-HLA-DQ De Novo DSA under Calcineurin Inhibitor or Belatacept Immunosuppression

V. Jucaud¹, H. Gebel², R. Bray², M. Polinsky³, M. Everly¹

5:30pm-7:30pm: Impact of Induction Choice and Early Steroid Withdrawal on Outcomes in HLA Zero Mismatched Kidney Transplant Recipients

C. Votruba¹, K. Holdener¹, B. Astor², F. Aziz², D. Mandelbrot²

5:30pm-7:30pm: Impact of Tacrolimus Formulation on Tacrolimus Level Coefficient of Variations

S. January¹, T. Horwedel², J. Hagopian¹, C. Carthon¹, A. Gharabagi³, R. Delos Santos⁴

5:30pm-7:30pm: Impacts of Mycophenolate Mofetile Addition to Very Low Exposure Everolimus and Calcineurine Inhibitor Based Immunosuppression in De Novo Kidney Transplantation 5 Years Results

Y. Watarai¹, S. Narumi¹, T. Tomosugi¹, M. Okada¹, K. Futamura², M. Tsujita², T. Hiramitsu¹, T. Kobayashi³, N. Goto²

5:30pm-7:30pm: Implementation of a De Novo Belatacept Protocol

D. Wojciechowski¹, M. Jacobs², K. Safa¹, H. Gilligan¹, H. Eliot¹, W. W. Williams, Jr¹

5:30pm-7:30pm: Long Term Outcomes in Kidney Transplant Recipients Receiving Everolimus (EVR) or Mycophenolate (MPS) in Combination with Tacrolimus (TAC)

K. Ficher, C. Rosso Felipe, Y. Cardoso Dreige, K. Linhares, A. Ferreira Brígido, S. Stopa, L. Viana, M. Cristelli, P. Gessolo Lins, W. Aguiar, H. Proença, R. Marco, M. Gerbase de Lima, H. Tedesco Silva Junior, J. Medina Pestana

5:30pm-7:30pm: Long-Term Efficacy and Safety of Everolimus Based Immunosuppression on De Novo Kidney Transplantation with 10 Years Follow-Up

Y. Watarai¹, S. Narumi¹, T. Tomosugi¹, K. Futamura², M. Okada¹, M. Tsujita², T. Hiramitsu¹, T. Kobayashi³, N. Goto²

5:30pm-7:30pm: Long-Term Outcomes of Early Conversion to Sirolimus-Based Immunosuppression in Children with Living Donor Kidney Transplants

B. Stotter¹, S. Lui¹, E. Weller², L. Ganapathi¹, M. Ferguson¹, A. Traum¹, M. Somers¹, N. Rodig¹

5:30pm-7:30pm: Long-Term Survival Analysis of Kidney Transplant Recipients Receiving Mizoribine as a Maintenance Immunosuppressant

J. Kim¹, D. Lee¹, J. Oh¹, J. Lee¹, H. Kim¹, Y. Son²

5:30pm-7:30pm: Optimizing Opportunity and Benefits of Steroid Avoidance in the New KAS Era

S. Sultan, M. Aull, R. Friedlander, V. K. Sharma, D. Serur, A. Watkins, S. Kapur, D. Dadhania

5:30pm-7:30pm: Outcomes in Kidney Transplant Recipients after Conversion from Tacrolimus to Belatacept-Based Regimens

H. Underwood, N. Lange, J. Hedvat, C. Brennan, D. Tsapepas, K. King, S. Husain, D. Salerno, S. Patel, S. Mohan, R. Crew

5:30pm-7:30pm: Outcomes of ABO Incompatible Transplant on Steroid Free Immunosuppression

A. Wang, D. Mishler, T. Taber, M. Yaqub, A. Sharfuddin, W. Goggins, O. Adebiyi

5:30pm-7:30pm: Race-Sex Effects on Immune Response Potential during Tacrolimus Minimization Therapy in Stable Renal Allograft Recipients

K. Tornatore¹, K. Attwood², R. Venuto³, H. Minderman⁴

5:30pm-7:30pm: Relationship between Comorbilities and Infectious Disease in Kidney Transplant Recipients Receiving Rituximab

A. Molina-Andújar¹, E. Hermida¹, J. Rovira², F. Cofan¹, P. Ventura-Aguiar¹, N. Esforzado¹, V. Torregrosa¹, D. Cucchiari¹, E. de Souza¹, I. Revuelta¹, F. Oppenheimer¹, F. Diekmann¹, G. Piñeiro¹

5:30pm-7:30pm: Risk Factors for Initial Sub- and Supra-Therapeutic Tacrolimus Trough Levels in Renal Transplant Recipients

M. Kapugi, K. Cunningham, C. D'Agostino, C. Kane, A. Novak, J. Schulte

5:30pm-7:30pm: Sirolimus (SRL) versus Everolimus (EVR) versus Mycophenolate (MPA) in Kidney Transplant Recipients Receiving Anti-Thymocyte Globulin Induction (r-ATG), Tacrolimus (TAC), and Prednisone

C. Rosso Felipe, L. Viana, M. Pontello Cristelli, J. Toniato, K. Ficher, S. Poletto, H. Proença, R. de Marco, M. Gerbase-Lima, A. Brigido, J. Medina Pestana, H. Tedesco-Silva

5:30pm-7:30pm: Tacrolimus Concentration/Dose Ratio is an Independent Predictor of Death-Censored Kidney Allograft Survival

T. Jouve¹, J. Noble¹, X. Fonrose², B. Janbon¹, G. Fiard³, P. Malvezzi¹, L. Rostaing¹

5:30pm-7:30pm: The Effect Of Tacrolimus Trough Variability On Kidney Transplant Outcomes

S. Heeney¹, K. R. Szempruch¹, R. Lee¹, A. Mintz², P. Serrano¹, R. Detwiler¹, C. Doligalski¹

5:30pm-7:30pm: The Effect of a Novel Dosing Protocol for the De Novo Use of LCP Tacrolimus in Kidney Transplant Recipients Managed on a Steroid-Free Maintenance Immunosuppression Regimen

R. Wolff¹, A. Nasstrom¹, C. Borscheid¹, C. Martin¹, A. Temelie¹, R. Spong², D. Keys², T. B. Dunn³

5:30pm-7:30pm: Time within Therapeutic Range: A Comparison of Three Tacrolimus Formulations within Ninety Days of Renal Transplant

S. Patel, K. Khalil, A. Lichvar, E. Benedetti, P. West-Thielke

5:30pm-7:30pm: Use of mTOR Inhibitors in Hypersensitized Kidney Transplant Recipients: Breaking False Myths

D. Cucchiari¹, A. Molina-Andujar¹, E. Montagud-Marrahi¹, F. J. Centellas-Pérez², I. Revuelta¹, F. Oppenheimer¹, F. Diekmann¹

« View all sessions from the 2019 American Transplant Congress